Francesca A. Chaloner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Francesca A. Chaloner has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Anna Mallach
UK Dementia Research Institute, Imperial College London, UK
1 shared publication - Carol Lee Wilkinson
Division of Developmental Medicine, Boston Children's Hospital, Boston, MA
1 shared publication - Carola I. Radulescu
UK Dementia Research Institute Centre, Department of Brain Sciences, Imperial College London, Hammersmith Hospital Campus, London, UK
1 shared publication Cigdem Gelegen
Wolfson Sensory, Pain and Regeneration Centre, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
1 shared publicationCraig A. Erickson
Division of Child and Adolescent Psychiatry, Cincinnati Children’s Hospital Medical Center, Cincinnati, USA
1 shared publicationFrancesca Osso
UK Dementia Research Institute Centre, Department of Brain Sciences, Imperial College London, Hammersmith Hospital Campus, London, UK
1 shared publication
Latest Publications
- Open Access
- 7 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Selective weakening of population-coupled synaptic activity in vivo in a mouse model of amyloid-beta pathology
Synaptic dysfunction in Alzheimer’s disease (AD) may drive synapse loss and cognitive impairment. Whether AD-related synaptic pathophysiology occurs globally, or in specific synapses, is unclear. We investigate in vivo AD-related synaptic dysfunction during early-stage amyloidosis in App NL-G-F mice. We find reduced presynaptic GABAergic proteins at c-Fos-positive excitatory neurons and increased calcium-mediated activity at excitatory and inhibitory neuronal assemblies. In vivo synaptic structure/function imaging finds reduced density and calcium-mediated activity of GABAergic axonal boutons. Rather than occurring globally, reduced synaptic activity is focused at GABAergic boutons strongly coupled to population activity in the amyloid microenvironment. The selective weakening of population-coupled synaptic activity also occurs in excitatory dendritic spines. Spatial transcriptomics finds parvalbumin-positive inhibitory neurons show differential gene expression associated with downregulated GABAergic synaptic transmission at early stages. We propose that early-stage AD-related synaptic pathophysiology is focused at population-coupled synapses, with molecular measures implicating abnormal synaptic processing as an early-stage feature in parvalbumin-positive interneurons.
- 7 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessSelective weakening of population-coupled synaptic activity in vivo in a mouse model of amyloid-beta pathology
Synaptic dysfunction in Alzheimer’s disease (AD) may drive synapse loss and cognitive impairment. Whether AD-related synaptic pathophysiology occurs globally, or in specific synapses, is unclear. We investigate in vivo AD-related synaptic dysfunction during early-stage amyloidosis in App NL-G-F mice. We find reduced presynaptic GABAergic proteins at c-Fos-positive excitatory neurons and increased calcium-mediated activity at excitatory and inhibitory neuronal assemblies. In vivo synaptic structure/function imaging finds reduced density and calcium-mediated activity of GABAergic axonal boutons. Rather than occurring globally, reduced synaptic activity is focused at GABAergic boutons strongly coupled to population activity in the amyloid microenvironment. The selective weakening of population-coupled synaptic activity also occurs in excitatory dendritic spines. Spatial transcriptomics finds parvalbumin-positive inhibitory neurons show differential gene expression associated with downregulated GABAergic synaptic transmission at early stages. We propose that early-stage AD-related synaptic pathophysiology is focused at population-coupled synapses, with molecular measures implicating abnormal synaptic processing as an early-stage feature in parvalbumin-positive interneurons.
- Open Access
- 9 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
A human electrophysiological signature of Fragile X pathophysiology is shared in V1 of Fmr1-/y mice
Predicting clinical therapeutic outcomes from animal studies using conserved electrophysiological phenotypes could facilitate developing treatments for neuropsychiatric disorders. Alpha oscillations in human resting-state electroencephalogram recordings are altered in many disorders, but whether these disruptions exist in mouse models is unknown. Here, we employed a uniform analytical method to show in males with fragile X syndrome (FXS) that alpha oscillations in humans and alpha-like oscillations in the visual cortex of Fmr1 -/y mice are slowed, with a stronger phenotype in adults than juveniles and a juvenile-specific power phenotype in both species. We find that alpha-like oscillations are disrupted by deletion of Fmr1 in cortical excitatory neurons and glia, reflect differential activity of two classes of GABAergic interneurons, and are more sensitive to activation of GABA B receptors by Arbaclofen in wild-type than Fmr1 -/y mice. Our framework reveals evolutionary conservation of alpha oscillation disruptions, enables a deeper understanding of FXS pathophysiology, and narrows the gap between treatment promise and practice.
- 9 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessA human electrophysiological signature of Fragile X pathophysiology is shared in V1 of Fmr1-/y mice
Predicting clinical therapeutic outcomes from animal studies using conserved electrophysiological phenotypes could facilitate developing treatments for neuropsychiatric disorders. Alpha oscillations in human resting-state electroencephalogram recordings are altered in many disorders, but whether these disruptions exist in mouse models is unknown. Here, we employed a uniform analytical method to show in males with fragile X syndrome (FXS) that alpha oscillations in humans and alpha-like oscillations in the visual cortex of Fmr1 -/y mice are slowed, with a stronger phenotype in adults than juveniles and a juvenile-specific power phenotype in both species. We find that alpha-like oscillations are disrupted by deletion of Fmr1 in cortical excitatory neurons and glia, reflect differential activity of two classes of GABAergic interneurons, and are more sensitive to activation of GABA B receptors by Arbaclofen in wild-type than Fmr1 -/y mice. Our framework reveals evolutionary conservation of alpha oscillation disruptions, enables a deeper understanding of FXS pathophysiology, and narrows the gap between treatment promise and practice.